Trials / Completed
CompletedNCT00506805
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Esanex Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNX-5422 | dose escalated, tablets every other day; undetermined duration until disease progression |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2007-07-25
- Last updated
- 2012-05-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00506805. Inclusion in this directory is not an endorsement.